Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful teams, win key customers, and navigate acquisitions and IPOs. Sofinnova Ventures invests in Life Science and Technology start-ups. Their professionals are seasoned business operators, possessing deep domain and investment expertise. They know how to help entrepreneurs build successful, global businesses.

Sofinnova Investments

New Enterprise Associates is a prominent venture capital firm focusing on investments in technology and healthcare startups. They help entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from the seed stage through the IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.

New Enterprise Associates

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of its industry.

Pfizer Venture Investments

PTV is a healthcare venture capital firm dedicated to enabling healthcare entrepreneurs and global innovation. It is comprised of a highly collaborative team of professionals, deeply experienced as investors and operators of life science companies. PTV focuses on mid-to-late stage companies with comparatively low technical, regulatory, and financial risk that are “with the grain” of healthcare economics – improving patient outcomes while decreasing costs – in markets with significant unmet clinical needs.

PTV Healthcare Capital

Correlation Ventures is a new breed of venture capital firm, leveraging world-class analytics to offer entrepreneurs and other venture capitalists a dramatically better option when they are seeking additional capital to complete a financing round.

Correlation Ventures

Osage University Partners is a venture capital firm focused on investing in startups that are commercializing university technologies. Osage partners with research universities to invest in their innovative startups shareing its investment profit with partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. To date, it has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 of their spinouts.

OUP (Osage University Partners)

Baxter Ventures invests in companies with innovative technologies, products and therapies with the ability to improve patient care globally and maximize value for investors and entrepreneurs.  Our focus includes therapeutic areas complementary to those of Baxter's Medical Products and BioScience businesses, as well as cutting-edge technologies and therapies outside of our current product portfolio that have sustainable long-term growth potential.  As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to develop products and therapies that advance patient care worldwide.

Baxter Ventures

Morningside Group is a private investment group founded in 1986 by the Chan family. The Chan family founded the Hang Lung Group in 1960. Today, the Hang Lung Group consists of Hang Lung Group Limited [0010.HK] and Hang Lung Properties Limited [0101.HK]. Both companies are listed on the Hong Kong Stock Exchange. Hang Lung Properties Limited is a constituent stock of the Hang Seng Index. Morningside Group invests in private equity and venture capital opportunities in North America, Europe, and the Asia Pacific. Since 1992, China has increasingly become a significant part of the groupâ€™s investment activities. Morningside Group has investments in the following sectors -- machinery manufacturing, high-tech, media, telecommunication, life science, education, and cleantech. The group is managed by experienced investment professionals who are entrepreneurial, have deep industry knowledge, and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is deeply committed to being socially responsible.  Providing access to educational opportunities and supporting scientific research are two major areas of focus for Morningside's philanthropic endeavors.

Morningside Group

Santé Ventures is a life sciences venture capital firm that invests exclusively in early-stage companies developing innovative new medical technologies or healthcare delivery models. The firm was founded in 2006 and has nearly $1 billion in capital under management.

Sante Ventures

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Celgene

Eastern Capital is a private, commercial lending company headquartered in Atlanta, Georgia.

Eastern Capital

Rock Springs Capital is an investment company situated in Baltimore, Maryland. The company specializes in offering advisory services, primarily focused on managing security portfolios and providing portfolio management solutions to businesses and institutional clients. Through its advisory activities, Rock Springs Capital aims to assist clients in optimizing their investment strategies and achieving their financial goals.

Rock Springs Capital

Mirna Therapeutics

Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

Mirna Therapeutics was an Austin-based clinical-stage biopharmaceutical company that developed a pipeline of microRNA-based oncology therapeutics. It implemented NetSuite's cloud-based business management software to drive its Sarbanes-Oxley (SOX) compliance success and enhance reporting and accounting functions. Mirna completed an initial public offering (IPO) and started trading on the Nasdaq exchange under the ticker symbol MIRN in October 2013. The company received a three-year, USD 16.8 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT) in 2012 to fund its cancer research programs. NetSuite enabled Mirna to meet the timely reporting compliance requirements associated with the CPRIT grant.

NetSuite Implementation Drives SOX Compliance Success, Better Reporting & Accounting Functions for Mirna Therapeutics

Promoting the health, well-being, and ethical treatment of animals

Animal Therapeutics

Mirna Therapeutics was an Austin-based clinical-stage biopharmaceutical company that developed a pipeline of microRNA-based oncology therapeutics. It implemented NetSuite's cloud-based business management software to drive its Sarbanes-Oxley (SOX) compliance success and enhance reporting and accounting functions. Mirna completed an initial public offering (IPO) and started trading on the Nasdaq exchange under the ticker symbol MIRN in October 2013. The company received a three-year, USD 16.8 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT) in 2012 to fund its cancer research programs. NetSuite enabled Mirna to meet the timely reporting compliance requirements associated with the CPRIT grant.

KeraVet Bio is a veterinary wound care company that develops keratin-based prescription products for dogs and cats. The company's flagship product, KeraVet Gel, is a wound management solution formulated to address mild and severe wounds, post-surgical incisions, and various dermatological conditions in pets. KeraVet Gel is made from a proprietary blend of keratin and utilizes patent-protected keratin technology. The product serves as a protective covering over wounds and is designed to improve healing time while reducing the need for cones or other lick deterrents. Clinical studies have shown that wounds treated with KeraVet Gel experienced significantly less swelling compared to those treated with triple antibiotic ointment in dogs and cats. The gel also demonstrated a reduction in licking behavior, with dogs licking 85% less and cats licking 87% less compared to a well-known wound management product. KeraVet Gel is available by prescription from veterinary practitioners and is distributed through major veterinary product distributors. The company is headquartered in the Innovation Quarter in Winston-Salem, North Carolina.

KeraVet Bio

Eir Pharmaceuticals was a development-stage biotechnology company that operated in multiple markets, including animal health, human consumer, and human health. The company's proprietary biotechnology platform was designed to develop and commercialize health, wellness, and pharmaceutical products across these diverse sectors. Eir Pharmaceuticals aimed to leverage its technology to capture value from various applications and target different customer segments within the broader healthcare industry.

EIR Pharmaceuticals

ProteaPex Therapeutics is a biotechnology company focused on developing therapies and dietary supplements for osteoarthritis. Their key product offering is ECPF-1, a novel therapeutic compound that has demonstrated chondroprotective properties in a rat model of osteoarthritis. In October 2023, the company presented findings from a study where ECPF-1 was administered through weekly injections to rats with osteoarthritis. The results showed that the knee cartilage of treated animals had less degradation and more healthy cartilage compared to untreated controls, even four weeks after the last injection. This suggests that ECPF-1 has the potential to slow the progression of osteoarthritis by protecting cartilage from further damage.
ProteaPex Therapeutics' platform technology revolves around Extracellular Matrix Protection Factors (ECPFs), a class of compounds derived from their research on cartilage biology and chondrocyte differentiation. In addition to ECPF-1, the company is also developing dietary supplement products based on this platform.

ProteaPex Therapeutics

MedcoVet offers a patented at-home laser therapy treatment device for pets suffering from arthritis, pain, and other inflammatory conditions. The company's technology allows veterinarians to prescribe clinical laser therapy for their patients to be administered in the comfort of their homes. MedcoVet's devices utilize photobiomodulation, a scientifically proven technique that relieves pain and expedites healing in animals.
The company partners with veterinarians, shipping the treatment devices directly to pet owners while providing telemedicine support to ensure proper usage. This approach enables veterinarians to offer laser therapy as a primary treatment modality without the inconvenience and expenses associated with in-clinic sessions. As of 2023, MedcoVet had 77 prescribers across 13 states in the US, experiencing a 50% quarter-on-quarter growth in prescribers during the previous quarter.
Several veterinary professionals and pet owners have reported significant improvements in their patients' mobility, reduced swelling and discomfort, and the ability to lower medication doses after using MedcoVet's at-home laser therapy devices. The company's technology has been praised for revolutionizing the application of laser therapy in veterinary medicine, making it more accessible and convenient for pet owners.

MedcoVet

Hilltop BioSciences, co-founded by Amanda Drobnis, is a veterinary biotech company pioneering the development of innovative regenerative therapies. Their flagship product, Regenaflex, is a room temperature, easy-to-use regenerative allograft available in injectable or membrane form. It stimulates cell-to-cell communication essential for healing soft tissue by delivering a potent combination of cytokines, microRNA, growth factors, and exosomes to the affected area. Regenaflex accelerates tissue healing, reduces inflammation, and minimizes scar tissue formation, making it a more effective and faster therapy compared to traditional treatments.
Initially focused on equine applications, with over 7 million horses in the US, Hilltop BioSciences has expanded into the companion animal market. Their product line includes Regenaflex-K9 for treating acute trauma, chronic infections, inflammation, non-healing wounds, anal gland abscesses, and fistulae in dogs. Regenaflex-M Biofilm is an anti-inflammatory, antimicrobial, and anti-adhesion scaffold that accelerates healing and prevents postoperative complications like adhesions and suture leakage after abdominal or orthopedic surgeries. PureOptic, their eye drop formulation, normalizes damaged ocular tissue resulting from injuries or diseases.
A key differentiator of Hilltop Bio's products is their long-term room-temperature storage, consistent composition in every dose, and the ability to be reconstituted and ready to use within a minute without any special equipment or time-consuming processing. As of January 2023, the company had raised funding led by Launchpad Venture Group and other Boston-based investment groups to expand its product pipeline leveraging its intellectual property portfolio.

Hilltop BioSciences

Companies that offer specialized therapeutics for the diagnosis, treatment, and management of cancer in animals. This includes areas such as cancer diagnosis, surgery, chemotherapy, and immunotherapy.

Companies that develop vaccines and drugs for pets and livestock based on advanced research and biotechnologies such as DNA technology, with a specific focus on the treatment and prevention of diseases and medical conditions in animals.

Companies that use regenerative techniques and technologies to promote tissue repair, regeneration, and healing in animals. This involves stem cell therapy, platelet-rich plasma (PRP) therapy, tissue engineering, gene therapy, and wound healing treatments.

Companies that provide veterinary diagnostic services, which include a wide range of tests, procedures, and laboratory services to diagnose, monitor, and manage the health and well-being of animals. This includes laboratory testing, diagnostic imaging, endoscopy, and genetic testing.

Companies that provide specialized treatments aimed at extending the lifespan and improving the overall health and quality of life of animals, including companion animals and livestock. These approaches are designed to address the challenges of aging, prevent age-related diseases, and enhance the well-being of aging animals.

Offers advanced diagnostics and insights for animal health using AI/ML

Offers products and services specifically designed for diagnostics and treatments based on advanced genomic sciences

Offers personalized preventive care and specialty care for animals

Mirna Therapeutics

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless